RDHLNasdaqPharmaceutical Preparations
RedHill Biopharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026
$0.50+0.02 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
RedHill Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Market Cap | $2.55M | $166.30M |
| Enterprise Value | -$2.61M | $88.19M |
| PS Ratio | 8.92 | 3.65 |
Enterprise value
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| EV / Sales | -9.11 | 2.51 |
Income (trailing twelve months)
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Revenue | $286.00K | $58.34M |
| Operating Income | -$7.94M | -$21.40M |
| EBITDA | -$7.94M | -$16.91M |
| EPS (Diluted) | $0.00 | -$0.83 |
Margins
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Operating Margin | -2776.9% | -44.0% |
| EBITDA Margin | -2776.9% | -30.2% |
| FCF Margin | -3376.2% | -9.27% |
Returns
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -1113.9% | -38.1% |
Growth
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -96.4% | 5.96% |
| Revenue Growth (3Y CAGR) | -83.3% | 2.25% |
| Revenue Growth (5Y CAGR) | -66.2% | 6.48% |
Balance sheet
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.16M | $61.43M |
| Net Cash (Debt) | $5.16M | $15.35M |
| Net Cash Per Share | $0.00 | $0.66 |
| Working Capital | -$16.99M | $76.81M |
Financial position
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Current Ratio | 0.34 | 3.34 |
| Quick Ratio | 0.20 | 2.44 |
| Interest Coverage | -5.45 | -6.26 |
Cash flow (trailing twelve months)
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$9.65M | -$12.35M |
| Capital Expenditures | -$5.00K | -$1.08M |
| Free Cash Flow | -$9.66M | -$20.22M |
| FCF Per Share | -$0.00 | -$0.42 |
Efficiency
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.39 |
| Revenue Per Employee | $22.00K | $404.87K |
| Employee Count | 13 | 74 |
Dividends and yields
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| FCF Yield | -378.3% | -8.72% |
Shares
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 50,923,300,000 | 58,127,000 |
| Shares Change (YoY) | 156.4% | 10.9% |
| Float | 48,630,400,000 | 49,136,700 |
| Shares Held by Insiders | 4.50% | 11.6% |
| Shares Held by Institutions | 0.00% | 59.4% |
Scores
| Measure | RedHill Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | -24.04 | -0.22 |
Calculated by StockData from RedHill Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.